Kvantify launches physics-based binding affinity-software for drug discovery with high accuracy and unprecedented speed

Koffee binding affinity is the latest addition to Kvantify’s computational drug discovery platform, helping the pharmaceutical and biotech industries design new drugs with an unmatched combination of speed and precision. 

COPENHAGEN, Denmark, Oct. 11, 2024 /PRNewswire/ — Kvantify has launched a new computational method that can accelerate the early phases of drug discovery. The method stands out significantly from other solutions on the market and is a strong addition to Kvantify’s computational drug discovery platform, Koffee. 

“Currently, benchmark tests show that our binding affinity tool is 100 times faster than comparable state-of-the-art methods with the same level of accuracy,” says Hans Henrik Knudsen, CEO of Kvantify. 

Binding affinity is a key parameter in drug discovery that refers to the strength of the interaction between a drug (or molecule) and its target protein. A molecule must interact strongly with a biological target to induce a therapeutic effect, and that is why this calculation is crucial in drug development. 

Fully physics-based  
When designing new drugs, there is a nearly endless number of possible variations and alterations, and that is why speedy and accurate calculations are so important.  

“Matching our speed with high accuracy gives us the option to push accurate physics-based binding affinity calculations further up the drug discovery pipeline,” says Hans Henrik Knudsen.  

Not only is the calculation time down to a few minutes, there are other advantages to Koffee binding affinity.  

“Our method requires no manual setup or parameterization. And as it is fully physics-based, there is no requirement for training data in contrast to machine learning and AI-based methods,” says Hans Henrik Knudsen

About Kvantify

Kvantify is a pioneering life science and quantum company based in Denmark. Their mission is to solve the toughest challenges in life sciences with a strong focus on drug discovery. Kvantify delivers pioneering solutions and services based on computational excellence that provide tangible value for life sciences companies today. 

Kvantify press team
contact@kvantify.com
+45 61759082

Photo – https://healthtechnologynet.com/wp-content/uploads/2024/10/Kvantify_CEO.jpg
Logo – https://healthtechnologynet.com/wp-content/uploads/2024/10/Kvantify_Logo.jpg

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/kvantify-launches-physics-based-binding-affinity-software-for-drug-discovery-with-high-accuracy-and-unprecedented-speed-302273089.html

SOURCE Kvantify ApS

Staff

Recent Posts

Waterdrop Inc. Released 2023 ESG Report: Adhere to both Sci-tech Innovation and Social Responsibility

BEIJING, Oct. 11, 2024 /PRNewswire/ -- Waterdrop Inc. released its Environmental, Social and Governance (ESG)…

2 hours ago

Cantargia Reports New Positive Results on Biomarkers and Safety in CAN10 Phase 1 Clinical Study

LUND, SE / ACCESSWIRE / October 11, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq…

2 hours ago

PMDS’ Largest Shareholder Requests EGM to Appoint New Non-Executive Directors Amid Management Changes

STOCKHOLM, SE / ACCESSWIRE / October 11, 2024 / PMD Device Solutions (FRA:8T0)(STO:PMDS) 11th October…

2 hours ago

Cosmo Pharmaceuticals Appoints New Chief Financial Officer

Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - October 11, 2024)…

6 hours ago

CeriBell, Inc. Announces Pricing of Upsized Initial Public Offering

SUNNYVALE, Calif., Oct. 10, 2024 /PRNewswire/ -- CeriBell, Inc. (Nasdaq: CBLL) ("Ceribell"), a commercial-stage medical…

8 hours ago

Britannia Launches Financing to Support Britannia Mining Solutions Lab Rollout

Toronto, Ontario--(Newsfile Corp. - October 10, 2024) - Britannia Life Sciences Inc. (CSE: BLAB) ("Britannia"…

11 hours ago